From perpetual haemosiderinuria to possible iron overload: iron redistribution in paroxysmal nocturnal haemoglobinuria patients on eculizumab by magnetic resonance imaging
From perpetual haemosiderinuria to possible iron overload: iron redistribution in paroxysmal nocturnal haemoglobinuria patients on eculizumab by magnetic resonance imaging(106 visite) Risitano AM, Imbriaco M, Marando L, Seneca E, Soscia E, Malcovati L, Iori AP, Pane F, Notaro R, Matarazzo M
Parole chiave: Eculizumab, Iron Metabolism, Iron Overload, Paroxysmal Nocturnal Haemoglobinuria, Complement Component C3, Ferritin, Hemosiderin, Abnormal Urine Composition, Adolescent, Adult, Clinical Article, Drug Response, Female, Ferritin Blood Level, Hemosiderinuria, Human, Hyperferritinemia, Kidney, Kidney Hemosiderosis, Letter, Liver, Liver Hemosiderosis, Nuclear Magnetic Resonance Imaging, Paroxysmal Nocturnal Hemoglobinuria, Priority Journal, Side Effect, Spleen, Antibodies, Monoclonal, Humanized, Middle Aged, Treatment Outcome, Young Adult, Humanized Therapeutic Use, Paroxysmal Blood Drug Therapy Immunology, Hemosiderin Urine, Iron Overload Blood, Magnetic Resonance Imaging Methods,
Affiliazioni:
*** IBB - CNR *** Division of Haematology, Department of Biochemistry and Medical Biotechnologies, Federico II University, Naples, Italy Department of Radiology, Federico II University, Naples, Italy Department of Haematology, University of Pavia Medical School, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy Department of Cellular Biotechnologies and Haematology, Università La Sapienza, Rome, Italy Core Research Laboratory, Istituto Toscano Tumori, Florence, Italy Department of Internal Medicine, Federico II University, Naples, Italy
Riferimenti:
Deugnier, Y., Turlin, B., Pathology of hepatic iron overload (2007) World Journal of Gastroenterology, 13, pp. 4755-476
Gandon, Y., Guyader, D., Heautot, J.F., Reda, M.I., Yaouanq, J., Buhé, T., Brissot, P., Deugnier, Y., Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging (1994) Radiology, 193, pp. 533-538
Hillmen, P., Young, N.S., Schubert, J., Brodsky, R.A., Socié, G., Muus, P., Röth, A., Luzzatto, L., The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria (2006) New England Journal of Medicine, 355, pp. 1233-1243
Kelly, R.J., Hill, A., Arnold, L.M., Brooksbank, G.L., Richards, S.J., Cullen, M., Mitchell, L.D., Hillmen, P., Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival (2011) Blood, 117, pp. 6786-6792
Mathieu, D., Rahmouni, A., Villeneuve, P., Anglade, M.C., Rochant, H., Vasile, N., Impact of magnetic resonance imaging on the diagnosis of abdominal complications of paroxysmal nocturnal hemoglobinuria (1995) Blood, 85, pp. 3283-3288
Parker, C., Omine, M., Richards, S., Nishimura, J., Bessler, M., Ware, R., Hillmen, P., Socié, G., Diagnosis and management of paroxysmal nocturnal hemoglobinuria (2005) Blood, 106, pp. 3699-3709. , International PNH Interest Group
Risitano, A.M., Notaro, R., Marando, L., Serio, B., Ranaldi, D., Seneca, E., Ricci, P., Rotoli, B., Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab (2009) Blood, 113, pp. 4094-4100
Risitano, A.M., Seneca, E., Marando, L., Imbraco, M., Soscia, E., Soscia, F., Micol Pizzuti, L., Rotoli, B., From renal siderosis due to perpetual hemosiderinuria to possible liver overload due to extravascular hemolysis: changes in iron metabolism in paroxysmal nocturnal hemoglobinuria (PNH) patients on eculizumab (2009) Blood, 114, p. 4031. , abs)
Risitano, A.M., Perna, F., Selleri, C., Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3 (2011) Mini Reviews in Medicinal Chemistry, 11, pp. 528-535
Röth, A., Hock, C., Konik, A., Christoph, S., Dührsen, U., Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena (2011) International Journal of Hematology, 93, pp. 704-714
Kelly, R. J., Hill, A., Arnold, L. M., Brooksbank, G. L., Richards, S. J., Cullen, M., Mitchell, L. D., Hillmen, P., Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival (2011) Blood, 117, pp. 6786-6792
Risitano, A. M., Notaro, R., Marando, L., Serio, B., Ranaldi, D., Seneca, E., Ricci, P., Rotoli, B., Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab (2009) Blood, 113, pp. 4094-4100
Risitano, A. M., Seneca, E., Marando, L., Imbraco, M., Soscia, E., Soscia, F., Micol Pizzuti, L., Rotoli, B., From renal siderosis due to perpetual hemosiderinuria to possible liver overload due to extravascular hemolysis: changes in iron metabolism in paroxysmal nocturnal hemoglobinuria (PNH) patients on eculizumab (2009) Blood, 114, p. 4031. , abs)
Risitano, A. M., Perna, F., Selleri, C., Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3 (2011) Mini Reviews in Medicinal Chemistry, 11, pp. 528-535
R th, A., Hock, C., Konik, A., Christoph, S., D hrsen, U., Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena (2011) International Journal of Hematology, 93, pp. 704-714
21 Records (17 escludendo Abstract e Conferenze). Impact factor totale: 65.725 (44.697 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 86.034 (60.141 escludendo Abstract e Conferenze).
ibb.cnr.it